title: Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?
abstract: Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.
authors.forename: Maristella
authors.initials: M
authors.lastname: Bianconi
authors.forename: Luca
authors.initials: L
authors.lastname: Faloppi
authors.forename: Michele
authors.initials: M
authors.lastname: Del Prete
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bittoni
authors.forename: Antonio
authors.initials: A
authors.lastname: Lopez-Beltran
authors.forename: Marina
authors.initials: M
authors.lastname: Scarpelli
authors.forename: Liang
authors.initials: L
authors.lastname: Cheng
authors.forename: Mario
authors.initials: M
authors.lastname: Scartozzi
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Montironi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib